Phesgo 600 mg Injection

Product Details

Phesgo 600 mg Injection – Dual Targeted Therapy for HER2-Positive Breast Cancer

Phesgo 600 mg Injection contains pertuzumab and trastuzumab, monoclonal antibodies designed to treat HER2-positive breast cancer. It is used in combination with chemotherapy to improve treatment outcomes in early and metastatic breast cancer.

Uses:

• Early HER2-Positive Breast Cancer
  • Administered as neoadjuvant (pre-surgery) or adjuvant (post-surgery) therapy in combination with chemotherapy.
• Metastatic HER2-Positive Breast Cancer
  • Used in combination with docetaxel in patients without prior anti-HER2 or chemotherapy for metastatic disease.

How Phesgo 600 mg Injection Works:

Phesgo combines two monoclonal antibodies:

1. Pertuzumab: Prevents HER2 dimerization, a process essential for cancer cell growth and survival.
2. Trastuzumab: Binds to HER2 receptors, inhibiting signaling pathways and marking cancer cells for destruction by the immune system.

Together, these agents block HER2 signaling more effectively, slowing tumor growth and reducing disease progression.

Common Side Effects:

• Fatigue
• Nausea
• Diarrhea
• Hair loss
• Rash
• Low blood cell counts
• Injection site reactions

Serious Side Effects (Seek Immediate Medical Attention):

• Heart problems, such as reduced ejection fraction or heart failure
• Severe infusion-related reactions (e.g., breathing difficulties, swelling)
• Severe diarrhea
• Allergic reactions, including rash, itching, or swelling
• Liver toxicity

Key Features:

• Dual-action therapy combining pertuzumab and trastuzumab
• Targets HER2-positive breast cancer cells effectively
• Convenient subcutaneous injection for rapid administration
• Proven to improve survival outcomes in HER2-positive breast cancer

Precautions:

• Heart Monitoring: Regular heart function tests are essential during treatment to monitor for potential cardiac issues.
• Pregnancy Warning: Phesgo is not recommended during pregnancy due to potential harm to the fetus. Women of childbearing age should use effective contraception.
• Infusion Reactions: Patients should be monitored during and after administration for severe reactions.

Frequently Asked Questions (FAQ):

What is Phesgo 600 mg Injection used for?
Phesgo is used for the treatment of early and metastatic HER2-positive breast cancer in combination with chemotherapy.

How does Phesgo 600 mg Injection work?
It combines pertuzumab and trastuzumab to block HER2 receptor signaling, effectively slowing cancer growth and improving survival outcomes.

How is Phesgo 600 mg Injection administered?
Phesgo is given as a subcutaneous injection, typically in a medical setting under the supervision of a healthcare provider.

Is Phesgo 600 mg Injection safe during pregnancy?
No, it is not recommended during pregnancy as it may harm the fetus. Women should use contraception during treatment and for at least 7 months after the last dose.

References:

• • Phesgo – https://journals.lww.com/md-journal/fulltext/2017/05190/safety_and_efficacy_evaluation_of_pertuzumab_in.19.aspx
  • FDA – https://pubmed.ncbi.nlm.nih.gov/25693012/